• We are a young and energetic research team working on the clinical, preclinical and pharmaceutical proteomics, with the purposes of discovering novel biomarkers for diagnosing/staging diseases, evaluating drug effects and elucidating of pathological/physiological processes.

  
  

  Our works are preliminarily based on the utilization of state-of-the-art liquid chromatography mass spectrometry (LC/MS) techniques for the investigation of extremely complex biological, clinical and pharmaceutical matrixes.

  
  

  We develop and apply novel analytical strategies that provides sensitive, comprehensive and accurate characterization of complex biological systems, as well as focused, highly-sensitive analysis of target proteins, pharmaceutical agents and endogenous markers. Many of our research projects are directed toward high-level clinical and pharmaceutical studies.

  
  

  We are particularly strong in studying a highly complex clinical/pharmaceutical system at proteome levels with high coverage, in determining of therapeutic proteins with extremely high sensitivity and accuracy, and in characterizing signal proteins without using antibody/antigen.

  
  

  We have strong connections with both renowned academic research groups and major pharmaceutical companies.

  
  

Recent works by Qu research team on Micro-scaffold Assisted Spatial Proteomics (MASP) and IonStar have been featured on UB SPPS School News! (01/2023)

Qu lab has published a novel method for accurate, absolute LC-MS quantification of target proteins in FFPE tissues, "Highly Accurate and Robust Absolute Quantification of Target Proteins in Formalin-Fixed Paraffin-Embedded (FFPE) Tissues by LC–MS" on Analytical Chemistry! See full article. (12/2022)

Qingqing Shen received 2022 Pharmaceutical Sciences Outstanding TA Awards. Congratulations! (12/2022)

Qu lab has published a novel method for spatial proteomics study, "In-depth mapping of protein localizations in whole tissue by micro-scaffold assisted spatial proteomics (MASP)" on Nature Communications! See full article.(12/2022)

Our "High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation" has been chosen to be the Featured Protocol on Nature Protocols! See more details. (12/2022)

Our lab has published a precise and powerful proteomic quantification strategy for large scale studies, named IonStar on Nature Protocols! See full article.(12/2022)

Min Ma has selected as a finalist in UB's seventh annual Three Minute Thesis (3MT) Competition. (12/2022)

Jie Pu presented a novel multiplexed immunoaffinity-MS assay for sensitive detection of adiponectin, leptin, and resistin in obesity samples on the Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR) conference (11/2022)

Xiaoyu Zhu presented her great work on Novel LC-MS-based Platform for Extensive Investigation on Antibody-Drug Conjugates Induced Ocular Toxicity in the 2022 Eastern Analytical Symposium (11/2022)

Dr. Jun Qu receives 2022 SUNY Chancellor's Award in Scholarship and Creative Activities (06/2022)